Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma

Min Jeong Oh, Jin Hyuk Choi, In Ho Kim, Yong Ho Lee, Joon Yong Huh, Yong Kyun Park, Kyu Wan Lee, Soo Yong Chough, Kap Soon Joo, Byung Sam Ku, Ho Suk Saw

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Epidermal growth factor receptor (EGFR) is overexpressed in a variety of malignancies, including breast, lung, gastric, and cervical carcinoma. Its overexpression has been associated with disease progression or poor prognosis in patients with cervical carcinoma. In the present study, the levels of EGFR were determined in serum from 38 patients with cervical carcinoma [invasive or recurrent carcinoma (n = 26) and carcinoma in situ (CIS; n = 12)] and 38 healthy female controls using ELISA. The mean serum level for EGFR in patients with invasive or recurrent carcinoma (165 ± 60 fmol/ml) was significantly elevated (P < 0.0001) compared with that of healthy controls (66 ± 17 fmol/ml) and also higher (P = 0.015) than that of patients with CIS (126 ± 25 fmol/ml). In addition, there was a significant difference in the mean serum levels of EGFR between patients with CIS and healthy controls (P < 0.0001). Thirty-five patients (92%) with cervical carcinoma [invasive or recurrent (n = 24) and CIS (n = 11)] had elevated serum EGFR levels above the cutoff value of 100 fmol/ml (defined as 2 SD above the mean of the controls). In conclusion, the serum EGFR level was elevated in a significant proportion of patients with cervical carcinoma, and it demonstrated an increasing tendency according to disease progression from normal tissue through CIS to invasive cervical carcinoma. Therefore, it may have a potential usefulness as a biological marker of cervical carcinoma.

Original languageEnglish
Pages (from-to)4760-4763
Number of pages4
JournalClinical Cancer Research
Volume6
Issue number12
Publication statusPublished - 2000 Jan 1

Fingerprint

Epidermal Growth Factor Receptor
Carcinoma
Serum
Disease Progression
Carcinoma in Situ
Stomach
Breast
Biomarkers
Enzyme-Linked Immunosorbent Assay
Lung

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Oh, M. J., Choi, J. H., Kim, I. H., Lee, Y. H., Huh, J. Y., Park, Y. K., ... Saw, H. S. (2000). Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clinical Cancer Research, 6(12), 4760-4763.

Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. / Oh, Min Jeong; Choi, Jin Hyuk; Kim, In Ho; Lee, Yong Ho; Huh, Joon Yong; Park, Yong Kyun; Lee, Kyu Wan; Chough, Soo Yong; Joo, Kap Soon; Ku, Byung Sam; Saw, Ho Suk.

In: Clinical Cancer Research, Vol. 6, No. 12, 01.01.2000, p. 4760-4763.

Research output: Contribution to journalArticle

Oh, MJ, Choi, JH, Kim, IH, Lee, YH, Huh, JY, Park, YK, Lee, KW, Chough, SY, Joo, KS, Ku, BS & Saw, HS 2000, 'Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma', Clinical Cancer Research, vol. 6, no. 12, pp. 4760-4763.
Oh, Min Jeong ; Choi, Jin Hyuk ; Kim, In Ho ; Lee, Yong Ho ; Huh, Joon Yong ; Park, Yong Kyun ; Lee, Kyu Wan ; Chough, Soo Yong ; Joo, Kap Soon ; Ku, Byung Sam ; Saw, Ho Suk. / Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. In: Clinical Cancer Research. 2000 ; Vol. 6, No. 12. pp. 4760-4763.
@article{69c7063baa8240dba8e18ee00322d4fd,
title = "Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma",
abstract = "Epidermal growth factor receptor (EGFR) is overexpressed in a variety of malignancies, including breast, lung, gastric, and cervical carcinoma. Its overexpression has been associated with disease progression or poor prognosis in patients with cervical carcinoma. In the present study, the levels of EGFR were determined in serum from 38 patients with cervical carcinoma [invasive or recurrent carcinoma (n = 26) and carcinoma in situ (CIS; n = 12)] and 38 healthy female controls using ELISA. The mean serum level for EGFR in patients with invasive or recurrent carcinoma (165 ± 60 fmol/ml) was significantly elevated (P < 0.0001) compared with that of healthy controls (66 ± 17 fmol/ml) and also higher (P = 0.015) than that of patients with CIS (126 ± 25 fmol/ml). In addition, there was a significant difference in the mean serum levels of EGFR between patients with CIS and healthy controls (P < 0.0001). Thirty-five patients (92{\%}) with cervical carcinoma [invasive or recurrent (n = 24) and CIS (n = 11)] had elevated serum EGFR levels above the cutoff value of 100 fmol/ml (defined as 2 SD above the mean of the controls). In conclusion, the serum EGFR level was elevated in a significant proportion of patients with cervical carcinoma, and it demonstrated an increasing tendency according to disease progression from normal tissue through CIS to invasive cervical carcinoma. Therefore, it may have a potential usefulness as a biological marker of cervical carcinoma.",
author = "Oh, {Min Jeong} and Choi, {Jin Hyuk} and Kim, {In Ho} and Lee, {Yong Ho} and Huh, {Joon Yong} and Park, {Yong Kyun} and Lee, {Kyu Wan} and Chough, {Soo Yong} and Joo, {Kap Soon} and Ku, {Byung Sam} and Saw, {Ho Suk}",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "6",
pages = "4760--4763",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma

AU - Oh, Min Jeong

AU - Choi, Jin Hyuk

AU - Kim, In Ho

AU - Lee, Yong Ho

AU - Huh, Joon Yong

AU - Park, Yong Kyun

AU - Lee, Kyu Wan

AU - Chough, Soo Yong

AU - Joo, Kap Soon

AU - Ku, Byung Sam

AU - Saw, Ho Suk

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Epidermal growth factor receptor (EGFR) is overexpressed in a variety of malignancies, including breast, lung, gastric, and cervical carcinoma. Its overexpression has been associated with disease progression or poor prognosis in patients with cervical carcinoma. In the present study, the levels of EGFR were determined in serum from 38 patients with cervical carcinoma [invasive or recurrent carcinoma (n = 26) and carcinoma in situ (CIS; n = 12)] and 38 healthy female controls using ELISA. The mean serum level for EGFR in patients with invasive or recurrent carcinoma (165 ± 60 fmol/ml) was significantly elevated (P < 0.0001) compared with that of healthy controls (66 ± 17 fmol/ml) and also higher (P = 0.015) than that of patients with CIS (126 ± 25 fmol/ml). In addition, there was a significant difference in the mean serum levels of EGFR between patients with CIS and healthy controls (P < 0.0001). Thirty-five patients (92%) with cervical carcinoma [invasive or recurrent (n = 24) and CIS (n = 11)] had elevated serum EGFR levels above the cutoff value of 100 fmol/ml (defined as 2 SD above the mean of the controls). In conclusion, the serum EGFR level was elevated in a significant proportion of patients with cervical carcinoma, and it demonstrated an increasing tendency according to disease progression from normal tissue through CIS to invasive cervical carcinoma. Therefore, it may have a potential usefulness as a biological marker of cervical carcinoma.

AB - Epidermal growth factor receptor (EGFR) is overexpressed in a variety of malignancies, including breast, lung, gastric, and cervical carcinoma. Its overexpression has been associated with disease progression or poor prognosis in patients with cervical carcinoma. In the present study, the levels of EGFR were determined in serum from 38 patients with cervical carcinoma [invasive or recurrent carcinoma (n = 26) and carcinoma in situ (CIS; n = 12)] and 38 healthy female controls using ELISA. The mean serum level for EGFR in patients with invasive or recurrent carcinoma (165 ± 60 fmol/ml) was significantly elevated (P < 0.0001) compared with that of healthy controls (66 ± 17 fmol/ml) and also higher (P = 0.015) than that of patients with CIS (126 ± 25 fmol/ml). In addition, there was a significant difference in the mean serum levels of EGFR between patients with CIS and healthy controls (P < 0.0001). Thirty-five patients (92%) with cervical carcinoma [invasive or recurrent (n = 24) and CIS (n = 11)] had elevated serum EGFR levels above the cutoff value of 100 fmol/ml (defined as 2 SD above the mean of the controls). In conclusion, the serum EGFR level was elevated in a significant proportion of patients with cervical carcinoma, and it demonstrated an increasing tendency according to disease progression from normal tissue through CIS to invasive cervical carcinoma. Therefore, it may have a potential usefulness as a biological marker of cervical carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0034485637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034485637&partnerID=8YFLogxK

M3 - Article

C2 - 11156231

AN - SCOPUS:0034485637

VL - 6

SP - 4760

EP - 4763

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -